KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Financing Activities (2016 - 2026)

Esperion Therapeutics filings provide 8 years of Cash from Financing Activities readings, the most recent being $30.2 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 13.81% to $30.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.2 million, a 58.16% decrease, with the full-year FY2025 number at $36.2 million, down 58.16% from a year prior.
  • Cash from Financing Activities hit $30.2 million in Q4 2025 for Esperion Therapeutics, up from $10.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $213.4 million in Q4 2021 to a low of -$30.4 million in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $4.1 million (2021), compared with a mean of $23.7 million.
  • Biggest five-year swings in Cash from Financing Activities: surged 3546.52% in 2023 and later plummeted 3811.12% in 2024.
  • Esperion Therapeutics' Cash from Financing Activities stood at $213.4 million in 2021, then tumbled by 114.23% to -$30.4 million in 2022, then skyrocketed by 114.73% to $4.5 million in 2023, then soared by 682.73% to $35.0 million in 2024, then dropped by 13.81% to $30.2 million in 2025.
  • The last three reported values for Cash from Financing Activities were $30.2 million (Q4 2025), $10.7 million (Q3 2025), and $2.8 million (Q2 2025) per Business Quant data.